EAACI Biologicals Guidelines—Recommendations for severe asthma
نویسندگان
چکیده
منابع مشابه
How safe are the biologicals in treating asthma and rhinitis?
A number of biological agents are available or being investigated for the treatment of asthma and rhinitis. The safety profiles of these biologic agents, which may modify allergic and immunological diseases, are still being elucidated. Subcutaneous allergen immunotherapy, the oldest biologic agent in current use, has the highest of frequency of the most serious and life-threatening reaction, an...
متن کاملPharmacological Therapy of Bronchial Asthma: The Role of Biologicals.
Bronchial asthma is a heterogeneous, complex, chronic inflammatory and obstructive pulmonary disease driven by various pathways to present with different phenotypes. A small proportion of asthmatics (5-10%) suffer from severe asthma with symptoms that cannot be controlled by guideline therapy with high doses of inhaled steroids plus a second controller, such as long-acting β2 agonists (LABA) or...
متن کاملBiologicals
Biological agents are currently a very important option for refractory autoimmune diseases [1]. From about ten years to now, several drugs are available to the clinical practice, mainly, in the rheumatology one. The main biological agents are antitumor necrosis factor (anti-TNF) medications, however there are other important drugs such as rituximab, which blocks lymphocyte B CD20, tocilizumab t...
متن کاملGuidelines for severe uncontrolled asthma.
Since the publication, 9 years ago, of the latest SEPAR (Spanish Society of Pulmonology and Thoracic Surgery) Guidelines on Difficult-to-Control Asthma (DCA), much progress has been made in the understanding of asthmatic disease. These new data need to be reviewed, analyzed and incorporated into the guidelines according to their level of evidence and recommendation. Recently, consensus document...
متن کاملEmerging therapies for severe asthma
Many patients with asthma have poorly controlled symptoms, and particularly for those with severe disease, there is a clear need for improved treatments. Two recent therapies licensed for use in asthma are omalizumab, a humanized monoclonal antibody that binds circulating IgE antibody, and bronchial thermoplasty, which involves the delivery of radio frequency energy to the airways to reduce air...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Allergy
سال: 2020
ISSN: 0105-4538,1398-9995
DOI: 10.1111/all.14425